Abstract
Purpose
To evaluate 125I seed brachytherapy combined with sorafenib in the treatment of patients with multiple lung metastases after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC).
Patients and methods
From July 2006 to December 2009, eight patients with multiple lung metastases after OLT for HCC underwent 125I brachytherapy combined with sorafenib, and laboratory and radiologic examinations were performed before and after the treatment. Changes in symptoms and survival time were noted at follow-up.
Results
The follow-up time ranged from 14 to 37 months. The local control rates of multiple lung metastases after OLT for HCC after 4, 6, 12, 18 and 24 months were 92.2, 82.4, 76.2, 73.3 and 72.2%, respectively. Four patients died (survival time 14, 15, 25 and 37 months, respectively), and four patients are alive at the time of this writing (follow-up time 18, 21, 26 and 30 months, respectively). The overall 1-, 2- and 3-year survival rates were 100, 50 and 12.5%, respectively. The median survival time was 21 months. Procedure-related complications were minimal.
Conclusion
125I brachytherapy combined with sorafenib is safe, feasible and promising approach in the treatment of patients with multiple lung metastases after OLT for HCC, but large-scale randomized clinical trials are necessary for confirmation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Blasko JC, John TM, Peter S et al (2002) Brachytherapy for carcinoma of the prostate: techniques, patients selection and clinical outcome. Semi Radiat Oncol 12:81–84
Calvisi DF, Ladu S, Gorden A et al (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117–1128
Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574
Chen Z, He F, Zeng F et al (2006) Impact of steroid withdrawal on recurrent rate of carcinoma after liver transplantation of hepatocellular carcinoma. Chin J Organ Transpl 27:156–159
Deuffic S, Poynard T, Buffat L et al (1998) Trends in primary liver cancer. Lancet 351:214–215
El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750
Ito Y, Sasaki Y, Horimoto M et al (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951–958
Klintmalm GB (2004) The history of organ transplantation in the Baylor Health Care System. Proc (Bayl Univ Med Cent) 17:23–34
Lee HH, Joh JW, Park JH et al (2005) Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma. Transplant Proc 37:1251–1253
Leslie TA, Kennedy JE, Illing RO et al (2008) High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response. Br J Radiol 81:564–571
Li Z (2000) Experimental measurements of dosimetric parameters on the transverse axis of a new 125I source. Med Phys 27:1275–1280
Ling CC (1992) Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23:81–87
Little SA, Fong Y (2001) Hepatocellular carcinoma: current surgical management. Semin Oncol 28:474–486
Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858
Llovet JM, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced hepatocellular carcinoma: results of a phase III randomized placebocontrolled trial. J Clin Oncol 25:LBA1
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Markus U, Ulrich S, Gabriele K et al (2006) Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36:1306–1311
Mazeron JJ, Noel G, Simon JM (2002) Head and neck brachytherapy. Semi Raidat Oncol 12:95–108
Mazzaferro V, Regalia E, Doci R et al (1996a) Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699
Mazzaferro V, Regalia E, Doci R et al (1996b) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699
Perez Saborido B, Loinaz Segurola C, Gimeno Calvo A et al (2003) Liver transplantation for hepatocellular carcinoma: our experience from 1986. Transplant Proc 35:1825–1826
Pokorny H, Gnant M, Rasoul-Rockenschaub S et al (2005) Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 5:788–794
Poon RT, Fan ST, Lo CM et al (2002) Long term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373–382
Ravaioli M, Grazi GL, Ercolani G et al (2004) Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 78:1780–1786
Schlitt HJ, Neipp M, Weimann A et al (1999) Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Onco 17:324
Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864–880
Shao ZX, Xu X, Zheng SS et al (2006) Serum α-fetoprotein alterations and tumor recurrence after liver transplantation for hepatocellular carcinoma patients. Chin J of Gen Surg 21:351–353
Sharma P, Balan V, Hernandez JL et al (2004) Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 10:36–41
Taylor-Robinson SD, Foster GR, Arora S et al (1997) Increase in primary liver cancer in the UK. Lancet 350:1142–1143
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Villanueva A, Newell P, Chiang DY et al (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76
Vivarelli M, Bellusci R, Cucchetti A et al (2002) Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74:1746–1751
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403
Zheng SS, Xu X, Liang TB et al (2005) Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 case. Chin J Surg 43:450–453
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, C., Zhang, F., Zhang, W. et al. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 136, 1633–1640 (2010). https://doi.org/10.1007/s00432-010-0821-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0821-z